TrialArthritis care & research2017

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

H Marzo-Ortega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.